Bullfrog AI Holdings, Inc. (BFRG) Stock

Healthcare · Health Information Services · Member of Other US Stocks

Bullfrog AI Holdings, Inc. (BFRG) closed at USD 0.53 on 2026-10-14, a change of -62.3 % over the past year, with a market capitalization of USD 9.92M.

Bullfrog AI Holdings, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Bullfrog AI Holdings, Inc. key figures

Previous close

USD 0.53 (2026-10-14)

1-year change

-62.3 %

Market cap

USD 9.92M

Enterprise value

USD 3.09M

P/E ratio (trailing)

-1.16

P/E ratio (forward)

-3.15

EPS (trailing)

-0.46

EPS (forward)

-0.17

PEG ratio

n/a

Price to book

1.42

Revenue growth

547.6 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

0.06

Employees

9

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Bullfrog AI Holdings, Inc.

Bullfrog AI Holdings, Inc. operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform to analyze preclinical and clinical data for biotechnology and pharmaceutical companies, and other organizations. It also develops BF-222, a novel formulation of mebendazole , which is in the first phase for the treatment of Glioblastoma; BF-223, a novel prodrug of mebendazole, which is in the preclinical stage for the treatment of Glioblastoma; and BF-114, which is in the discovery phase, to treat obesity and chronic liver diseases. The company has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. It has a partnership with the Lieber Institute for Brain Development (LIBD) to enable the discovery and development of precision treatments for CNS disorders. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Bullfrog AI Holdings, Inc. and compare it with other stocks.